Last 12 months
Inside the activity.
2 purchase rows · 107 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 2 | 3 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 12 |
| Jul 2026 | 0 | 26 |
| Aug 2026 | 0 | 18 |
| Sep 2026 | 0 | 15 |
| Oct 2026 | 0 | 9 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2026 Filed Apr 24, 2026 20:30 UTC |
WILSON JAMES NDirector
|
GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-177404 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,095,532 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 23:34 UTC |
Guyer WilliamChief Development Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-148497 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 23:34 UTC |
Guyer WilliamChief Development Officer
|
SaleCommon Stock | 20,000 | $40.97 | $819,400.00 |
DisclosureSEC source: 0001193125-26-148497 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,231 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $40.85 to $41.30 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 23:34 UTC |
Guyer WilliamChief Development Officer
|
Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0001193125-26-148497 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 23:29 UTC |
WILSON JAMES NDirector
|
GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-148488 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,097,532 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:27 UTC |
BELANOFF JOSEPH KDirector · Chief Executive Officer
|
SaleCommon Stock | 26,198 | $50.07 | $1,311,825.55 |
DisclosureSEC source: 0001193125-26-129143 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,918,326 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.32 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:55 UTC |
WILSON JAMES NDirector
|
GiftCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-122139 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,102,532 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:54 UTC |
Guyer WilliamChief Development Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 11,767 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-122136 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 11,767 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:54 UTC |
Guyer WilliamChief Development Officer
|
SaleCommon Stock | 11,767 | $36.01 | $423,729.67 |
DisclosureSEC source: 0001193125-26-122136 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,231 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:54 UTC |
Guyer WilliamChief Development Officer
|
Exercise / conversionCommon Stock | 11,767 | $21.65 | $254,755.55 |
DisclosureSEC source: 0001193125-26-122136 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 21:07 UTC |
BAKER G LEONARD JRDirector
|
PurchaseCommon Stock | 24,218 | $33.56 | $812,836.00 |
DisclosureSEC source: 0001201715-26-000007 · form4-03192026_090326.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,146,631 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.44 to $33.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 21:07 UTC |
BAKER G LEONARD JRDirector
|
PurchaseCommon Stock | 75,782 | $33.00 | $2,500,972.72 |
DisclosureSEC source: 0001201715-26-000007 · form4-03192026_090326.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,122,413 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.43 to $33.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 13, 2026 Filed Mar 18, 2026 00:03 UTC |
WILSON JAMES NDirector
|
GiftCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111536 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,106,532 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 23:52 UTC |
MAHONEY DAVID LDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.86 | $0.00 |
DisclosureSEC source: 0001193125-26-111518 · ownership.xml · derivative · entry 6 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2026-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 23:52 UTC |
MAHONEY DAVID LDirector
|
OtherCommon Stock | 24,531 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111518 · ownership.xml · nonDerivative · entry 4 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,237,145 F2 · kind: Transfer of shares without consideration to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 23:52 UTC |
MAHONEY DAVID LDirector
|
GiftCommon Stock | 24,531 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111518 · ownership.xml · nonDerivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · kind: Transfer of shares without consideration to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 23:52 UTC |
MAHONEY DAVID LDirector
|
Tax withholdingCommon Stock | 5,469 | $32.15 | $175,828.35 |
DisclosureSEC source: 0001193125-26-111518 · ownership.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,531 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 23:52 UTC |
MAHONEY DAVID LDirector
|
Exercise / conversionCommon Stock | 30,000 | $5.86 | $175,800.00 |
DisclosureSEC source: 0001193125-26-111518 · ownership.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:30 UTC |
Guyer WilliamChief Development Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,233 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-096653 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,767 Underlying: Common Stock · 8,233 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:30 UTC |
Guyer WilliamChief Development Officer
|
SaleCommon Stock | 8,233 | $35.99 | $296,346.01 |
DisclosureSEC source: 0001193125-26-096653 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,231 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:30 UTC |
Guyer WilliamChief Development Officer
|
Exercise / conversionCommon Stock | 8,233 | $21.65 | $178,244.45 |
DisclosureSEC source: 0001193125-26-096653 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 01:26 UTC |
Lyon Joseph DouglasSee Remarks
|
Tax withholdingCommon Stock | 89 | $35.97 | $3,201.33 |
DisclosureSEC source: 0001193125-26-092166 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,230 F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F6 · price: The closing price on March 2, 2026 was used to calculate the withholding obligation. F7 · balance_after: Includes 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 . 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 01:24 UTC |
Maduck SeanSee Remarks
|
Tax withholdingCommon Stock | 110 | $35.97 | $3,956.70 |
DisclosureSEC source: 0001193125-26-092164 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,977 F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F6 · price: The closing price on March 2, 2026 was used to calculate the withholding obligation. F7 · balance_after: Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 01:21 UTC |
Robb Gary CharlesChief Business Officer
|
Tax withholdingCommon Stock | 121 | $35.97 | $4,352.37 |
DisclosureSEC source: 0001193125-26-092158 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,503 F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F6 · price: The closing price on March 2, 2026 was used to calculate the withholding obligation. F7 · balance_after: Includes 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, and 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 224 share underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 01:20 UTC |
Mokari AtabakChief Financial Officer
|
Tax withholdingCommon Stock | 96 | $35.97 | $3,453.12 |
DisclosureSEC source: 0001193125-26-092155 · ownership.xml · nonDerivative · entry 3 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,257 F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F6 · price: The closing price on March 2, 2026 was used to calculate the withholding obligation. F7 · balance_after: Includes 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:26 UTC |
Lyon Joseph DouglasSee Remarks
|
GrantCommon Stock | 398 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092166 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,319 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:26 UTC |
Lyon Joseph DouglasSee Remarks
|
GrantCommon Stock | 398 | $35.97 | $14,316.06 |
DisclosureSEC source: 0001193125-26-092166 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,921 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:24 UTC |
Maduck SeanSee Remarks
|
GrantCommon Stock | 454 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092164 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,087 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:24 UTC |
Maduck SeanSee Remarks
|
GrantCommon Stock | 454 | $35.97 | $16,330.38 |
DisclosureSEC source: 0001193125-26-092164 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,633 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:21 UTC |
Robb Gary CharlesChief Business Officer
|
GrantCommon Stock | 499 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092158 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,624 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 224 share underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:21 UTC |
Robb Gary CharlesChief Business Officer
|
GrantCommon Stock | 499 | $35.97 | $17,949.03 |
DisclosureSEC source: 0001193125-26-092158 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,125 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 224 share underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:21 UTC |
Guyer WilliamChief Development Officer
|
GrantCommon Stock | 498 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092157 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,231 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:21 UTC |
Guyer WilliamChief Development Officer
|
GrantCommon Stock | 498 | $35.97 | $17,913.06 |
DisclosureSEC source: 0001193125-26-092157 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,733 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:20 UTC |
Mokari AtabakChief Financial Officer
|
GrantCommon Stock | 397 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092155 · ownership.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,353 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:20 UTC |
Mokari AtabakChief Financial Officer
|
GrantCommon Stock | 397 | $35.97 | $14,280.09 |
DisclosureSEC source: 0001193125-26-092155 · ownership.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,956 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:19 UTC |
Lyon Joseph DouglasSee Remarks
|
GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $35.70 | $0.00 |
DisclosureSEC source: 0001193125-26-089029 · ownership.xml · derivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:17 UTC |
BELANOFF JOSEPH KDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 460,000 | $0.00 Strike: $35.70 | $0.00 |
DisclosureSEC source: 0001193125-26-089023 · ownership.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,000 Underlying: Common Stock · 460,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:16 UTC |
Mokari AtabakChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $35.70 | $0.00 |
DisclosureSEC source: 0001193125-26-089018 · ownership.xml · derivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:14 UTC |
Maduck SeanSee Remarks
|
GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $35.70 | $0.00 |
DisclosureSEC source: 0001193125-26-089013 · ownership.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:14 UTC |
Hunt HazelChief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $35.70 | $0.00 |
DisclosureSEC source: 0001193125-26-089012 · ownership.xml · derivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:13 UTC |
Robb Gary CharlesChief Business Officer
|
GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $35.70 | $0.00 |
DisclosureSEC source: 0001193125-26-089010 · ownership.xml · derivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:13 UTC |
Guyer WilliamChief Development Officer
|
GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $35.70 | $0.00 |
DisclosureSEC source: 0001193125-26-089009 · ownership.xml · derivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:45 UTC |
WILSON JAMES NDirector
|
Exercise / conversionStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001193125-26-076999 · ownership.xml · derivative · entry 8 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:45 UTC |
WILSON JAMES NDirector
|
OtherCommon Stock | 89,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-076999 · ownership.xml · nonDerivative · entry 4 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,134,532 F2 · kind: Transfer of shares without consideration to the James N. Wilson and Pamela D. Wilson Trust. F3 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:45 UTC |
WILSON JAMES NDirector
|
GiftCommon Stock | 89,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-076999 · ownership.xml · nonDerivative · entry 3 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · kind: Transfer of shares without consideration to the James N. Wilson and Pamela D. Wilson Trust. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:45 UTC |
WILSON JAMES NDirector
|
Tax withholdingCommon Stock | 10,636 | $36.48 | $388,001.28 |
DisclosureSEC source: 0001193125-26-076999 · ownership.xml · nonDerivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,364 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on February 26, 2026. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:45 UTC |
WILSON JAMES NDirector
|
Exercise / conversionCommon Stock | 100,000 | $3.88 | $388,000.00 |
DisclosureSEC source: 0001193125-26-076999 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:26 UTC |
Hunt HazelChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001193125-26-046881 · ownership.xml · derivative · entry 3 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:26 UTC |
Hunt HazelChief Scientific Officer
|
Tax withholdingCommon Stock | 77,968 | $41.31 | $3,220,858.08 |
DisclosureSEC source: 0001193125-26-046881 · ownership.xml · nonDerivative · entry 2 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,437 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on February 26, 2026. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:26 UTC |
Hunt HazelChief Scientific Officer
|
Exercise / conversionCommon Stock | 150,000 | $3.88 | $582,000.00 |
DisclosureSEC source: 0001193125-26-046881 · ownership.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.